Maria Cristina Figueroa Magalhães

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Early Breast Cancer

Prognostic Factors

Ejection Fraction

Top Venues

Journal of personalized medicine

European journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Francisco Cezar Aquino de Moraes, Vitor Kendi Tsuchiya Sano, Caroline R M Pereira, Estella Aparecida de Laia, Carlos Stecca, Maria Cristina Figueroa Magalhães, Rommel Mario Rodríguez Burbano
Treatment-related adverse events in patients with advanced breast cancer receiving adjuvant AKT inhibitors: a meta-analysis of randomized controlled trials. European journal of clinical pharmacology (2024)
Francisco Cezar Aquino de Moraes, Gustavo de Oliveira Almeida, Vinícius Freire Costa Alves, Jonathan N Priantti, Giovanna da Conceição Gomes, Sarah Vitória Bristot Carnevalli, Thiago Madeira, Maysa Vilbert, Carlos Stecca, Maria Cristina Figueroa Magalhães, Marianne Rodrigues Fernandes, Ney Pereira Carneiro Dos Santos
Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials. Journal of personalized medicine 14 (5) (2024)
Francisco Cezar Aquino de Moraes, Vitor Kendi Tsuchiya Sano, Caroline R M Pereira, Estella Aparecida de Laia, Carlos Stecca, Maria Cristina Figueroa Magalhães, Rommel Mario Rodríguez Burbano
Treatment-related adverse events in patients with advanced breast cancer receiving adjuvant AKT inhibitors: a meta-analysis of randomized controlled trials. European journal of clinical pharmacology 80 (9) (2024)
Francisco Cezar Aquino de Moraes, Gustavo de Oliveira Almeida, Vinícius Freire Costa Alves, Jonathan N Priantti, Giovanna da Conceição Gomes, Sarah Vitória Bristot Carnevalli, Thiago Madeira, Maysa Vilbert, Carlos Stecca, Maria Cristina Figueroa Magalhães, Marianne Rodrigues Fernandes, Ney Pereira Carneiro Dos Santos
Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials. Journal of personalized medicine 14 (5) (2024)